Waypoint Capital Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Waypoint Capital Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-154,466	Closed	-$16.6M	–	136
2023 Q1	$16.6M	Sell	154,466 -16,715	-10%	-$1.92M	5.4%	2
2022 Q4	$18.8M	Sell	171,181 -21,894	-11%	-$1.42M	6.53%	2
2022 Q3	$11.4M	Buy	193,075 +40,410	+26%	+$1.85M	4.97%	2
2022 Q2	$4.31M	Sell	152,665 -83,091	-35%	-$2.41M	1.96%	16
2022 Q1	$8.72M	Buy	235,756 +83,091	+54%	+$3.28M	5.13%	4
2021 Q4	$6.04M	Buy	+152,665	New	+$4.78M	4.14%	6

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Waypoint Capital Advisors's RXDX Position: Q2 2023 in Review

Waypoint Capital Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 154,466 shares — an estimated $16.6M sold.

Waypoint Capital Advisors first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $18.8M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Waypoint Capital Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Waypoint Capital Advisors sold 154,466 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $16.6M.
Waypoint Capital Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Waypoint Capital Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $18.8M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Waypoint Capital Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.